Pappas Capital Announces the Passing of…

CeNeRx BioPharma, Inc., a clinical stage company developing and commercializing innovative treatments for diseases of the central nervous system, today announced completion of a $9 million financing. The financing includes a $5 million credit facility from MidCap Financial and $4 million in convertible debt from existing investors Aisling Capital, L Capital Partners and Pappas Ventures. CeNeRx plans to use the proceeds to advance its pipeline of promising clinical and preclinical stage compounds for mood disorders, neurodegenerative conditions and pain and spasticity.